Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma: The MASTER Trial (primary analysis)

Single-arm phase 2 MRD-adapted Dara-KRd with AHCT (n=123). Primary endpoint MRD <10^-5: 80% overall (78%, 82%, and 79% for 0, 1, and 2+ HRCAs); 66% reached MRD <10^-6; 71% had two consecutive MRD-negative assessments and entered treatment-free surveillance. Two-year PFS was 87% (91%, 97%, and 58% for 0, 1, and 2+ HRCAs). 12-month incidence of MRD resurgence or progression after cessation was 4%, 0%, and 27% by HRCA group. Not a randomized trial, so filed as level 2 despite being MRD-guided.

J Clin OncolPubMed 34898239